5,956 Shares in Illumina, Inc. $ILMN Purchased by Wick Capital Partners LLC

by · The Markets Daily

Wick Capital Partners LLC bought a new stake in shares of Illumina, Inc. (NASDAQ:ILMN – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 5,956 shares of the life sciences company’s stock, valued at approximately $781,000.

A number of other hedge funds have also made changes to their positions in ILMN. Elyxium Wealth LLC purchased a new position in Illumina during the fourth quarter valued at approximately $25,000. Board of the Pension Protection Fund purchased a new position in shares of Illumina during the 4th quarter valued at $26,000. Creative Capital Management Investments LLC increased its stake in shares of Illumina by 160.0% in the fourth quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock worth $26,000 after acquiring an additional 120 shares during the last quarter. TD Waterhouse Canada Inc. purchased a new stake in shares of Illumina during the fourth quarter worth $26,000. Finally, Laurel Wealth Advisors LLC acquired a new stake in Illumina during the fourth quarter valued at $26,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Stock Up 1.8%

ILMN opened at $161.93 on Friday. The firm has a market cap of $24.50 billion, a P/E ratio of 29.44, a price-to-earnings-growth ratio of 2.98 and a beta of 1.50. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.36 and a current ratio of 1.75. The business has a 50 day moving average price of $144.52 and a 200 day moving average price of $135.98. Illumina, Inc. has a twelve month low of $88.00 and a twelve month high of $177.22.

Illumina (NASDAQ:ILMN – Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.05 by $0.10. The company had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The company’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same quarter last year, the firm posted $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Research analysts forecast that Illumina, Inc. will post 5.21 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on ILMN. Guggenheim upped their target price on Illumina from $170.00 to $180.00 and gave the stock a “buy” rating in a research report on Monday, June 1st. Royal Bank Of Canada started coverage on Illumina in a report on Thursday, May 14th. They issued an “outperform” rating and a $170.00 price objective on the stock. Barclays lifted their target price on shares of Illumina from $110.00 to $122.00 and gave the company an “underweight” rating in a research note on Friday, May 1st. Weiss Ratings upgraded shares of Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, June 3rd. Finally, Evercore reaffirmed an “outperform” rating on shares of Illumina in a research note on Friday, May 1st. Eight research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $142.12.

View Our Latest Report on Illumina

Insider Activity

In other news, insider Scott M. Davies sold 615 shares of the firm’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $160.00, for a total value of $98,400.00. Following the sale, the insider directly owned 21,568 shares of the company’s stock, valued at approximately $3,450,880. This trade represents a 2.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Scott D. Ericksen sold 1,500 shares of Illumina stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $150.10, for a total value of $225,150.00. Following the completion of the transaction, the chief accounting officer owned 14,946 shares in the company, valued at $2,243,394.60. The trade was a 9.12% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 1,003,154 shares of company stock worth $155,600,208. Insiders own 2.90% of the company’s stock.

About Illumina

(Free Report)

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

See Also

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN – Free Report).